ライフサイエンスコーパス: thrombocytopenia

1 and schedule (all five patients had grade 4 thrombocytopenia).

2 h transition to a DOAC during HIT-associated thrombocytopenia).

3 n vivo and was a significant risk factor for thrombocytopenia.

4 d undergo increased cell death, resulting in thrombocytopenia.

5 d are not indicated for patients with severe thrombocytopenia.

6 er-risk myelodysplastic syndromes and severe thrombocytopenia.

7 n FLI1 mutations have been ascribed to cause thrombocytopenia.

8 ng periodic fevers with immunodeficiency and thrombocytopenia.

9 ed congenital dyserythropoietic anemias with thrombocytopenia.

10 s, and 1 late death occurred from autoimmune thrombocytopenia.

11 n mouse and human Nfe2, Fli1 and Runx1 cause thrombocytopenia.

12 usions to VLBW infants with mild to moderate thrombocytopenia.

13 is, unlike other antibody-mediated causes of thrombocytopenia.

14 nger RNA (mRNA) expression profiles and mild thrombocytopenia.

15 count, fatigue, neutropenia, and sepsis, and thrombocytopenia.

16 afety, and remission in children with immune thrombocytopenia.

17 c children with persistent or chronic immune thrombocytopenia.

18 ly severe at birth to predispose newborns to thrombocytopenia.

19 p of patients with suspected heparin-induced thrombocytopenia.

20 ay be associated with immune-mediated severe thrombocytopenia.

21 cy, its primary adverse effect is high-grade thrombocytopenia.

22 nd results in variable bleeding symptoms and thrombocytopenia.

23 -1-risk myelodysplastic syndromes and severe thrombocytopenia.

24 emia, eight (67%) neutropenia, and ten (83%) thrombocytopenia.

25 let activation with resultant thrombosis and thrombocytopenia.

26 utropenia (19% each); lymphopenia (14%); and thrombocytopenia (10%).

27 rse events included neutropenia (53% v 49%), thrombocytopenia (13% v 29%), anemia (7% v 15%), leukope

28 nfection (21 [20%]), anaemia (19 [18%]), and thrombocytopenia (16 [15%]).

29 lated adverse events included fatigue (16%), thrombocytopenia (16%), and neutropenia (10%).

30 mmonly reported grade 3 or 4 toxicities were thrombocytopenia (16%), fatigue (15%), and hyponatremia

31 of 154 vs three [2%] of 152 with imatinib), thrombocytopenia (19 [12%] of 154 vs ten [7%] of 152 wit

32 eveal (1) the mechanism of selinexor-induced thrombocytopenia, (2) an effective way to reverse the do

33 oup vs 22 [31%] of 70 in the placebo group), thrombocytopenia (20 [28%] vs 16 [23%]), hypertension (n

34 n and included lymphopenia, neutropenia, and thrombocytopenia (21 [100%] patients for each toxicity);

35 26%] in the bendamustine monotherapy group), thrombocytopenia (21 [11%] vs 32 [16%]), anaemia (15 [8%

36 cluded anaemia (37 [38%] of 97 patients) and thrombocytopenia (21 [22%] of 97), with 18 (19%) patient

37 rade >/= 3 adverse events were anemia (36%), thrombocytopenia (21%), and hypokalemia (17%).

38 Neutropenia (22%) and thrombocytopenia (22%) were the most common grade 3-4 he

39 89%] patients in MAP vs 268 [90%] in MAPIE), thrombocytopenia (231 [78% in MAP vs 248 [83%] in MAPIE)

40 ore frequent with trastuzumab emtansine were thrombocytopenia (24 [6%] of 403 patients vs five [3%] o

41 ic (neutropenia [49.7%], anemia [33.0%], and thrombocytopenia [24.1%]).

42 /kg weekly group were anaemia (59 [26%]) and thrombocytopenia (25 [11%]) compared with neutropenia (4

43 69%] of 52 patients on the 10-day schedule), thrombocytopenia (25 [49%] vs 22 [42%]), neutropenia (20

44 [23%] of 154 patients in the placebo group), thrombocytopenia (26 [17%] vs ten [6%]), and diarrhoea (

45 were neutropenia (46 [51%] of 91 patients), thrombocytopenia (26 [29%]), anaemia (26 [29%]), decreas

46 -4 adverse events were infrequent other than thrombocytopenia (26 [58%]).

47 they were neutropenia (99 [47%] of 209) and thrombocytopenia (27 [13%]).

48 and nausea [38%]) and grade 3/4 cytopenias (thrombocytopenia [29%] and anemia [15%]).

49 of 83) without increased risk of infection, thrombocytopenia (30 [18%] vs 23 [28%]), leucopenia (13

50 treated patients in the control group were: thrombocytopenia (32 [9%] vs 23 [6%]), fatigue (six [2%]

51 were the most common grade 3/4 events, with thrombocytopenia (32%), neutropenia (27%), anemia (23%),

52 penia (97 [39%] of 252), anaemia (61 [24%]), thrombocytopenia (33 [13%]), sepsis (28 [11%]), and pneu

53 41 [18%] patients in the placebo group) and thrombocytopenia (34 [15%] patients in the lenalidomide

54 patients in the best supportive care group), thrombocytopenia (35 [19%] vs six [7%]), neutropenia (31

55 b group), hypertension (41 [9%] vs 12 [3%]), thrombocytopenia (39 [8%] vs 43 [9%]), and pneumonia (32

56 s, including thyroiditis (3), hemolysis (1), thrombocytopenia (4), and neutropenia (1).

57 vs 15 [3%]), pneumonia (42 [9%] vs 39 [9%]), thrombocytopenia (41 [9%] vs 43 [9%]), fatigue (31 [7%]

58 All patients experienced thrombocytopenia (41 episodes in 275 courses; 15%).

59 group vs 145 [51%] in the placebo group) and thrombocytopenia (43 [15%] in each group).

60 mon toxic effects reported in the study were thrombocytopenia (43 [96%] patients), anaemia (41 [91%])

61 de 3 or 4 AEs were hematologic, particularly thrombocytopenia (45%).

62 daratumumab group and the control group were thrombocytopenia (45.3% and 32.9%, respectively), anemia

63 rade 3 to 4 drug-related adverse events were thrombocytopenia (47%), neutropenia (32%), anemia (27%),

64 st frequent grade 3 or 4 adverse events were thrombocytopenia (48%) and neutropenia (37%).

65 %]) and the most common grade 4 toxicity was thrombocytopenia (50 [63%]).

66 uded anemia (all); hypoalbuminemia (all) and thrombocytopenia (6).

67 ents in the trastuzumab emtansine group were thrombocytopenia (70 [14%] of 490), increased aspartate

68 eable toxicity; fatigue (87%), nausea (78%), thrombocytopenia (70%), diarrhea (70%), and vomiting (48

69 es were neutropenia (96%), leukopenia (84%), thrombocytopenia (82%), anemia (74%), and fatigue (72%);

70 cluding anemia (15%), neutropenia (11%), and thrombocytopenia (9%).

71 ytoreduction (lymphopenia, neuthropenia, and thrombocytopenia) achieved by the modified protocol was

72 sociated with lower risk were female gender, thrombocytopenia, acute coronary syndrome, atrial fibril

73 We report two patients that developed severe thrombocytopenia after Zika virus (ZIKV) infection.

74 gible participants were children with immune thrombocytopenia aged 1 year to 17 years and mean platel

75 events in all three groups were neutropenia, thrombocytopenia, anaemia, and febrile neutropenia or in

76 Expected serious adverse events were: thrombocytopenia, anaemia, and lymphopenia (all for pati

77 mg twice a day with at least one of grade 3 thrombocytopenia, anaemia, or bleeding at grade 3 or wor

78 ulated secretion of VWF leading to transient thrombocytopenia and a subsequent deficiency of plasma V

79 a disease characterized by hemolytic anemia, thrombocytopenia and acute renal failure with multiple o

80 mposite: hospitalization for bleeding and/or thrombocytopenia and death from hemorrhage or infection.

81 plan-Meier method was lower in patients with thrombocytopenia and decreased with thrombocytopenia sev

82 Here we show that both the transient thrombocytopenia and GPVI ectodomain shedding depend on

83 is a microangiopathic disorder diagnosed by thrombocytopenia and hemolytic anemia, associated with a

84 ne oxygenator (prevalence of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia re

85 Prevalence of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia-re

86 tic transcription factor, is associated with thrombocytopenia and impaired platelet responses on acti

87 The disease included marked thrombocytopenia and inflammatory disease characteristic

88 Thrombocytopenia and intraventricular hemorrhage (IVH) a

89 er-risk myelodysplastic syndromes and severe thrombocytopenia and is clinically effective in raising

90 Thrombocytopenia and leukopenia were also observed.

91 latelets and coagulation proteins results in thrombocytopenia and low concentrations of clotting fact

92 Thrombocytopenia and neutropenia of any grade were seen

93 garding hematologic toxicities, grade 3 to 4 thrombocytopenia and neutropenia were each experienced b

94 Within 6 days, the patient had developed thrombocytopenia and neutropenia, which was initially th

95 elet production and function, culminating in thrombocytopenia and platelet dysfunction.

96 Under conditions of thrombocytopenia and relative stem cell deficiency in th

97 no correlation was found between severity of thrombocytopenia and risk for IVH.

98 e attempt to exclude nonautoimmune causes of thrombocytopenia and secondary ITP.

99 rformed, after which the association between thrombocytopenia and the host response was tested, as ev

100 rogress to life-threatening complications of thrombocytopenia and thrombosis.

101 CU who were presumed to have heparin-induced thrombocytopenia and underwent antiplatelet factor 4/hep

102 erse events (grade 4 pneumonitis and grade 4 thrombocytopenia) and subsequently died.

103 n effective way to reverse the dose-limiting thrombocytopenia, and (3) a novel role for XPO1 in megak

104 hy characterized by intravascular hemolysis, thrombocytopenia, and acute kidney failure.

105 Microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury were found in

106 A peripheral blood smear revealed anemia, thrombocytopenia, and blast cells, and a diagnosis of ac

107 ed on trimester of presentation, severity of thrombocytopenia, and coincident clinical and laboratory

108 ension in three patients (10%), and anaemia, thrombocytopenia, and diarrhoea in two patients each (6%

109 events were neutropenia, leukopenia, anemia, thrombocytopenia, and fatigue.

110 gic adverse effects (grade 4 neutropenia and thrombocytopenia, and grade 3 neutropenia, both requirin

111 significant comorbidities, hypoalbuminemia, thrombocytopenia, and high lactate dehydrogenase level,

112 sult in acute liver toxicity, transaminitis, thrombocytopenia, and injury to the vascular endothelium

113 , and 3% of the patients experienced anemia, thrombocytopenia, and leukopenia, respectively.

114 key features of disease being intense fever, thrombocytopenia, and leukopenia.

115 Grade 3 or 4 neutropenia, thrombocytopenia, and lymphopenia occurred in 1%, 2%, an

116 ytophilum infection and showed splenomegaly, thrombocytopenia, and monocytopenia.

117 yperkalemia, hypoglycemia, photosensitivity, thrombocytopenia, and more rare adverse reactions.

118 by microangiopathic hemolytic anemia, severe thrombocytopenia, and organ ischemia linked to dissemina

119 ios, develop hepatosplenomegaly, anemia, and thrombocytopenia, and succumb to a rapidly progressing a

120 ported grade 3 or 4 toxicities were fatigue, thrombocytopenia, anemia, lymphopenia, and leukopenia.

121 ted abnormal blood lineage distribution, and thrombocytopenia as well as recovered osteoblast and HSP

122 ns may be an effective strategy to limit the thrombocytopenia associated with pig-to-human hepatic xe

123 PERSEVERE in children with septic shock and thrombocytopenia-associated multiple organ failure (TAMO

124 The proportion of patients with grade 3 or 4 thrombocytopenia, asthenia, and liver toxicity was signi

125 0 mg; G3 fatigue at 250 mg; G2 nausea and G4 thrombocytopenia at 350 mg; and G3 vomiting and G3 diarr

126 al DLTs were observed: G4 neutropenia and G4 thrombocytopenia at 400 mg and G4 thrombocytopenia (two

127 survival, which is probably attributable to thrombocytopenia at GVHD onset (73 x 10(9) cells per L [

128 ide and fludarabine, higher CAR T-cell dose, thrombocytopenia before lymphodepletion, and manufacturi

129 latelet counts <25 x 10(9) per L) or grade 4 thrombocytopenia before platelet transfusion, with 25 x

130 lure (TAMOF), and in those without new onset thrombocytopenia but with multiple organ failure (MOF).

131 We determined that selinexor causes thrombocytopenia by blocking thrombopoietin (TPO) signal

132 n three patients during cycle 1 (one grade 4 thrombocytopenia [cohort 2], one grade 3 QT prolongation

133 hort 3], and one grade 3 fatigue and grade 4 thrombocytopenia [cohort 3]).

134 Clinical studies indicate that thrombocytopenia correlates with the development of seve

135 al control recipient demonstrated persistent thrombocytopenia despite platelet administration after t

136 Thrombocytopenia develops in 5% to 10% of women during p

137 t the algorithm criteria for heparin-induced thrombocytopenia diagnosis and seven of those had docume

138 However, the severity of thrombocytopenia did not correlate with the risk for IVH

139 lasts of 50% or less, and had either grade 4 thrombocytopenia due to bone marrow insufficiency (plate

140 tate transaminase increase (15%), anemia and thrombocytopenia (each 14%), diarrhea (11%), and pneumon

141 h syndrome (WAS), a disease characterized by thrombocytopenia, eczema, immunodeficiency, and autoimmu

142 74 patients with small-cell lung cancer were thrombocytopenia (eight [11%]), pleural effusion (six [8

143 ts; most common were neutropenia (26 [53%]), thrombocytopenia (eight [16%]), anaemia (seven [14%]), f

144 or; had significantly higher heparin-induced thrombocytopenia enzyme-linked immunosorbent assays opti

145 verse events (AEs) included anemia, fatigue, thrombocytopenia, fever, and injection site reactions.

146 [44%] of 18 patients), anaemia (six [33%]), thrombocytopenia (five [28%]), increased alanine aminotr

147 used to manage fetal or neonatal alloimmune thrombocytopenia (FNAIT) in subsequent pregnancies.

148 aemia (six [38%]), neutropenia (four [25%]), thrombocytopenia (four [25%]), anaemia (four [25%]), fev

149 eucopenia (30 patients vs four patients) and thrombocytopenia (four vs zero) occurred more often in p

150 e a day but none was tolerable, with DLTs of thrombocytopenia, gastrointestinal events (diarrhoea, vo

151 an oral thrombopoietin receptor agonist, for thrombocytopenia (grade 4) treatment in adult patients w

152 which was unrelated to the vaccine (grade 3 thrombocytopenia, grade 3 device-related infection, grad

153 Patients with grade 3/4 thrombocytopenia had received significantly higher radia

154 risk of death increased with the severity of thrombocytopenia (hazard ratio, 1.65; 95% CI, 1.31-2.08

155 ntraindicated abciximab use in patients with thrombocytopenia (hazard ratio, 2.23; 95% confidence int

156 5.9 [2.7-12.6]; p < 0.0001) and very severe thrombocytopenia (hazard ratio, 25.9 [10.7-62.9], p < 0.

157 ffective in resolving preexisting TTP signs; thrombocytopenia, hemolytic anemia, and organ damage cou

158 factor and platelets, which account for the thrombocytopenia, hemolytic anemia, schistocytes, and ti

159 Heparin-induced thrombocytopenia (HIT) is a prothrombotic disorder initi

160 Heparin-induced thrombocytopenia (HIT) is a relatively common prothrombo

161 Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction occur

162 Heparin-induced thrombocytopenia (HIT) is an immune complication of hepa

163 Heparin-induced thrombocytopenia (HIT) is characterized by a high incide

164 Life-threatening heparin-induced thrombocytopenia (HIT) is treated with the alternative n

165 gulants for the treatment of heparin-induced thrombocytopenia (HIT), few data are available comparing

166 ive options for treatment of heparin-induced thrombocytopenia (HIT).

167 accuracy of immunoassays for heparin-induced thrombocytopenia (HIT).

168 including weight loss, organomegaly, anemia, thrombocytopenia, hypercytokinemia, and tissue inflammat

169 rse events were anaemia in 32 (5%) patients, thrombocytopenia in 15 (2%) patients, neutropenia in ten

170 mmunotherapy toxicity consisted of grade 3-4 thrombocytopenia in 48 (84%) of 57 patients and neutrope

171 th grades) in the BAT arm, and grade 3 and 4 thrombocytopenia in 5.2% and 1.7% of ruxolitinib vs 0% (

172 ion protein that inhibits the development of thrombocytopenia in a murine model of immune thrombocyto

173 Persisting thrombocytopenia in critically ill patients is associate

174 nt was hyperglycemia in 11 (29.7%) patients, thrombocytopenia in eight (21.6%), infection in seven (1

175 nd describe the incidence and time course of thrombocytopenia in extracorporeal membrane oxygenation

176 tor agonist, might be effective in improving thrombocytopenia in lower-risk myelodysplastic syndromes

177 The prognostic impact of thrombocytopenia in patients supported by extracorporeal

178 production disorders and help to explain the thrombocytopenia in patients with Bernard-Soulier syndro

179 , a defect which might be the major cause of thrombocytopenia in patients.

180 t work through the differential diagnosis of thrombocytopenia in pregnancy based on trimester of pres

181 nding and managing the more common causes of thrombocytopenia in pregnancy.

182 n described herein is crucial to help reduce thrombocytopenia in selinexor patients, allowing them to

183 currence of overdiagnosis of heparin-induced thrombocytopenia in surgical patients with critical illn

184 a and three patients (4%) reported grade 3-4 thrombocytopenia in the group receiving best available t

185 sis and trauma are the most common causes of thrombocytopenia in the ICU.

186 Overtreatment of heparin-induced thrombocytopenia in the surgical ICU continues even with

187 penia (five [28%]), anaemia (four [22%], and thrombocytopenia in three [17%]).

188 at were reported in the niraparib group were thrombocytopenia (in 33.8%), anemia (in 25.3%), and neut

189 n 78% of the patients), anemia (in 43%), and thrombocytopenia (in 38%).

190 f 44 patients, the most common of which were thrombocytopenia (in nine [20%] of 44 patients), neutrop

191 f 0.8 mg/kg every 3 weeks, including grade 4 thrombocytopenia (in two of two patients at that dose le

192 We report two cases of transient severe thrombocytopenia induced by DDAVP treatment.

193 roangiopathy, HDL also largely prevented the thrombocytopenia induced by injection of high doses of h

194 Thrombocytopenia is a common, multifactorial, finding in

195 Thrombocytopenia is a life-threatening complication in p

196 Platelets are essential for hemostasis, and thrombocytopenia is a major clinical problem.

197 Thrombocytopenia is a major side effect of a new class o

198 Heparin-induced thrombocytopenia is a profoundly dangerous, potentially

199 Heparin-induced thrombocytopenia is a prothrombotic disorder caused by a

200 trum of disorders of keratinization in which thrombocytopenia is also part of the phenotype.

201 Thrombocytopenia is an independent risk factor for poor

202 These data show that admission thrombocytopenia is associated with enhanced mortality a

203 In myelodysplastic syndromes, thrombocytopenia is associated with mortality, but treat

204 tient samples to show that selinexor-induced thrombocytopenia is indeed reversible when TPO agonists

205 We investigated whether thrombocytopenia is independently predictive of poor out

206 cells (MDSCs) in the pathogenesis of immune thrombocytopenia (ITP) and identify a novel mechanism by

207 ombocytopenia (TMAT) from donors with immune thrombocytopenia (ITP) can result in significant bleedin

208 Treatment options for immune thrombocytopenia (ITP) in pregnancy are limited, and evi

209 s in patients with chronic/persistent immune thrombocytopenia (ITP) increased platelet counts and red

210 Immune thrombocytopenia (ITP) is an autoimmune bleeding disorde

211 Immune thrombocytopenia (ITP) is an immune-mediated acquired bl

212 Immune thrombocytopenia (ITP) occurs in 2 to 4/100 000 adults a

213 Refractory immune thrombocytopenia (ITP) was previously defined as lack of

214 t of children and adults with primary immune thrombocytopenia (ITP) who do not respond to, cannot tol

215 thrombocytopenia in a murine model of immune thrombocytopenia (ITP).1 The unique aspect of this prote

216 h are expressed in different mouse models of thrombocytopenia, lack both Ras and Rap1GAP activity and

217 rt PMF was enriched in patients with anemia, thrombocytopenia, leukopenia, higher blast count, sympto

218 fter cardiac surgery, with persistent severe thrombocytopenia likely reflecting a high degree of phys

219 A profound thrombocytopenia limits hepatic xenotransplantation in t

220 ression higher than grade 2, most frequently thrombocytopenia (n = 18), though none required autologo

221 iting toxicities, including fatigue (n = 2), thrombocytopenia (n = 2), and elevated AST/ALT (n = 1),

222 2%]), tinnitus and dizziness (n=1 [2%]), and thrombocytopenia (n=1 [2%]).

223 pacritinib group, and anaemia (n=16 [15%]), thrombocytopenia (n=12 [11%]), dyspnoea (n=3 [3%]), and

224 s through week 24 were anaemia (n=37 [17%]), thrombocytopenia (n=26 [12%]), and diarrhoea (n=11 [5%])

225 atitis (n=5), atrial fibrillation (n=3), and thrombocytopenia (n=3).

226 lence of grade 1 to 2 toxicities, especially thrombocytopenia, nausea, and elevation of liver enzymes

227 adverse effects, including thyroid toxicity, thrombocytopenia, nausea, fatigue, jaundice, and muscle

228 00%) compared with 19 of 125 heparin-induced thrombocytopenia-negative patients (15%).

229 Anaemia, thrombocytopenia, neutropenia, oesophagitis, diarrhoea,

230 ectively; further decline in anticoagulants; thrombocytopenia; neutrophilia and endotoxemia.

231 ither group, irrespective of cause, included thrombocytopenia (none in the ruxolitinib group vs two [

232 sening grade 3 or 4 neutropenia, anemia, and thrombocytopenia occurred in 24%, 41%, and 29% of the pa

233 No cases of grade 3-4 anaemia or thrombocytopenia occurred with ruxolitinib; one patient

234 No thrombocytopenia occurred.

235 Thrombocytopenia of grade 3 and grade 4 severity occurre

236 rcumvents the dose-limiting, BCL-XL-mediated thrombocytopenia of its less selective predecessor navit

237 s safe and effective in children with immune thrombocytopenia of more than 6 months' duration.

238 iency in hyaluronidase-2 (Hyal-2) results in thrombocytopenia of unknown mechanism.

239 gender (OR, 0.77; CI, 0.66-0.89; P < 0.001), thrombocytopenia (OR, 0.79; CI, 0.62-1.00; P = 0.049), a

240 7; 95% confidence interval [CI], 1.26-2.76), thrombocytopenia (OR, 2.06; 95% CI, 1.26-3.38), and hepa

241 on in solid tumors or chronic, stable severe thrombocytopenia) or that were addressed partially (inva

242 trols, patients with acute or chronic immune thrombocytopenia, or patients with other thrombocytopeni

243 ion doses to RM than patients with grade 1/2 thrombocytopenia (P = 0.02).

244 atients with acute coronary syndrome, severe thrombocytopenia (patients treated for hematological or

245 sent on 198 of 212 patient-days (93.4%) with thrombocytopenia (PCT, <100000/muL) when a platelet tran

246 rolling for significant clinical factors and thrombocytopenia, platelet transfusions did not have a s

247 ference in mortality between heparin-induced thrombocytopenia positive and negative patients.

248 Heparin-induced thrombocytopenia positive patients were younger; all und

249 patients were identified as heparin-induced thrombocytopenia positive.

250 n, or fondaparinux: 10 of 10 heparin-induced thrombocytopenia-positive patients (100%) compared with

251 Heparin-induced thrombocytopenia-positive patients were defined as those

252 imary outcome: age, vasopressor requirement, thrombocytopenia, preexisting kidney disease, failed ven

253 ividuals in 3 unrelated families with severe thrombocytopenia progressing to trilineage bone marrow f

254 induced thrombocytopenia and heparin-induced thrombocytopenia related thrombosis, 8.3 and 7.3, respec

255 induced thrombocytopenia and heparin-induced thrombocytopenia-related thrombosis among extracorporeal

256 al criteria for diagnosis of heparin-induced thrombocytopenia remain unclear, contributing to unneces

257 In children with chronic immune thrombocytopenia, romiplostim induced a high rate of pla

258 eview, the authors highlight heparin-induced thrombocytopenia's risk factors, clinical presentation,

259 -1 presented all hallmarks of TMA, including thrombocytopenia, schistocytosis, anemia, and VWF-positi

260 ligible patients were those 16 or older with thrombocytopenia secondary to bone marrow failure, requi

261 lly life-threatening complications of severe thrombocytopenia seen in a variety of medical settings i

262 roup vs seven [14%] of 52 in the BAT group), thrombocytopenia (seven [7%] vs three [6%]), and abdomin

263 nts with thrombocytopenia and decreased with thrombocytopenia severity.

264 enia (14 [16%]), pneumonia (seven [8%]), and thrombocytopenia (six [7%] vs 19 [11%] in the idelalisib

265 al events, amputations, recurrent/persistent thrombocytopenia, skin lesions) and bleedings.

266 Severe fever with thrombocytopenia syndrome (SFTS) is a novel tick-borne v

267 Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-bor

268 Severe fever with thrombocytopenia syndrome (SFTS) is an emerging viral di

269 gent viral pathogen termed severe fever with thrombocytopenia syndrome virus (SFTSV) is responsible f

270 152 vs five [3%] of 154 with ponatinib) and thrombocytopenia (ten [7%] of 152 vs 19 [12%] of 154 wit

271 to interpret the results of heparin-induced thrombocytopenia testing.

272 ients at this dose level experienced grade 4 thrombocytopenia that required transfusion, a dose-limit

273 mia, increased alanine aminotransferase, and thrombocytopenia (three [1%] each).

274 Transplant-mediated alloimmune thrombocytopenia (TMAT) from donors with immune thromboc

275 l ICUs and were suspected of heparin-induced thrombocytopenia to identify how often patients were cor

276 identify the mechanism of selinexor-induced thrombocytopenia to relieve it and improve its clinical

277 Recent trends in the management of immune thrombocytopenia translate into more women contemplating

278 ecreased neutrophil count, pancytopenia, and thrombocytopenia (two [3%] each).

279 75 in the best available therapy group) and thrombocytopenia (two [3%] vs six [8%]).

280 nia and G4 thrombocytopenia at 400 mg and G4 thrombocytopenia (two patients) at 500 mg.

281 istry of Patients With Acute Heparin-induced Thrombocytopenia Type II; NCT01304238).

282 - 20 x 10/L), and very severe (< 20 x 10/L) thrombocytopenia was 50%, 54%, and 7%, respectively.

283 Thrombocytopenia was a risk factor for intraventricular

284 Grade 3-4 thrombocytopenia was more common in the combination grou

285 Thrombocytopenia was observed in 70%, leukopenia in 59%;

286 Thrombocytopenia was present in all patients.

287 DLTs (grade 4 thrombocytopenia) was noted in two of the patients.

288 nfounders, moderate, severe, and very severe thrombocytopenia were independently associated with 90-d

289 r bilirubin, coagulopathy, leukocytosis, and thrombocytopenia were independently associated with DILI

290 Both levels of thrombocytopenia were independently associated with incr

291 Durations of severe neutropenia and thrombocytopenia were prolonged in the intensive arm, bu

292 (with no exclusions for baseline anaemia or thrombocytopenia) were randomly assigned (2:1) to receiv

293 ed with 113 of 190 patient-days (59.5%) with thrombocytopenia when no platelet transfusion was given.

294 rse events occurred in eight (62%) patients; thrombocytopenia, which occurred in three (23%) patients

295 mal gain-of-function phenotype, evidenced by thrombocytopenia, which quickly relapses back to normal

296 Thrombocytopenia with symptomatic bleeding at or above W

297 ought to assess the association of admission thrombocytopenia with the presentation, outcome, and hos

298 lobally associated with an increased risk of thrombocytopenia within the first 24 hours following the

299 This is the first study to investigate thrombocytopenia within the first 24 hours of septic sho

300 Wiskott-Aldrich syndrome (WAS), X-linked thrombocytopenia (XLT), and X-linked neutropenia, which